经动脉化疗栓塞联合微波消融与经动脉化疗栓塞治疗BCLC B期肝细胞癌的比较
Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma.
作者信息
Zhang Rusi, Shen Lujun, Zhao Long, Guan Zhaoming, Chen Qifeng, Li Wang
机构信息
Department of Medical Imaging and Interventional Radiology; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine; Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, People's Republic of China.
Department of Medical Imaging and Interventional Radiology; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou, People's Republic of China.
出版信息
Diagn Interv Radiol. 2018 Jul;24(4):219-224. doi: 10.5152/dir.2018.17528.
PURPOSE
We aimed to compare the clinical effectiveness of combination therapy of transarterial chemoembolization (TACE) and microwave ablation (MWA) with TACE monotherapy in BCLC stage B HCC patients with tumor size ≤7 cm and tumor number ≤5.
METHODS
We retrospectively reviewed 150 BCLC stage B HCC patients who had received TACE monotherapy or TACE-MWA combination therapy in our hospital from March 2007 to April 2016. The patients were matched by propensity score at the ratio of 1:2 by optimal method. The median follow-up period was 16 months. The overall survival, tumor response and progression-free survival were compared between the two groups by Kaplan-Meier method and Log rank test.
RESULTS
Tumor response (complete or partial response or stable disease) rates at 6, 12, 18, 24 months were 55.5%, 37.3%, 21.3%, 15.8% for TACE group, and 74%, 47.8%, 35%, 31.8% for TACE-MWA group, respectively. The survival rates at 1, 3, 5 years were 77.5%, 42.1%, 21% for TACE group and 93.1%, 79%, 67.7% for TACE-MWA group, respectively. Compared with TACE group, the TACE-MWA group had significantly improved progression-free survival (P = 0.044) and overall survival (P = 0.002).
CONCLUSION
TACE-MWA combination therapy has better clinical effectiveness than TACE monotherapy in BCLC stage B patients with tumor size ≤7 cm and tumor number ≤5.
目的
我们旨在比较经动脉化疗栓塞术（TACE）联合微波消融术（MWA）与单纯TACE治疗巴塞罗那临床肝癌（BCLC）分期为B期、肿瘤大小≤7 cm且肿瘤数量≤5个的肝癌患者的临床疗效。
方法
我们回顾性分析了2007年3月至2016年4月在我院接受单纯TACE治疗或TACE-MWA联合治疗的150例BCLC分期为B期的肝癌患者。采用倾向评分法按1:2的比例进行最佳匹配。中位随访期为16个月。采用Kaplan-Meier法和Log rank检验比较两组患者的总生存期、肿瘤反应和无进展生存期。
结果
TACE组在6、12、18、24个月时的肿瘤反应（完全缓解或部分缓解或疾病稳定）率分别为55.5%、37.3%、21.3%、15.8%，TACE-MWA组分别为74%、47.8%、35%、31.8%。TACE组1、3、5年生存率分别为77.5%、42.1%、21%，TACE-MWA组分别为93.1%、79%、67.7%。与TACE组相比，TACE-MWA组的无进展生存期（P = 0.044）和总生存期（P = 0.002）均有显著改善。
结论
对于肿瘤大小≤7 cm且肿瘤数量≤5个的BCLC分期为B期的患者，TACE-MWA联合治疗比单纯TACE治疗具有更好的临床疗效。
Zotero 插件